Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 59Neoplasms 6Neoplasm Metastasis 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Ovarian Neoplasms 3Neoplasms by Site 3Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteitis Deformans 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Bevacizumab 6Paclitaxel 5Leucovorin 5Irinotecan 5Fluorouracil 5napabucasin 4Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Ocoxin 3Imatinib Mesylate 3Drug Therapy 3palbociclib 2entinostat 2encorafenib 2Oxaliplatin 2Levoleucovorin 2Folfox protocol 2Everolimus 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2spartalizumab 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1olaparib 1linifanib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Digestive System Neoplasms × ribociclib × Clear all
NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Incyte Corporation

Phase 1 Recruiting
604 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡